Eurizon SLJ Capital’s Pfizer PFE Stock Holding History

Eurizon SLJ Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$239K	Hold	9,906	–	–	0.09%	116
2026 Q1	$278K	Buy	+9,906	New	+$264K	0.13%	90

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Eurizon SLJ Capital's PFE Position: Q2 2026 in Review

Eurizon SLJ Capital held its Pfizer (PFE) position steady in Q2 2026 at 9,906 shares worth $239K. The position accounts for 0.09% of the portfolio, ranked #116.

Eurizon SLJ Capital first reported a position in PFE in Q1 2026 and has held it in 2 quarters since. The position peaked at $278K in Q1 2026. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Eurizon SLJ Capital held 9,906 shares of Pfizer worth $239K as of Q2 2026.
Eurizon SLJ Capital left its Pfizer share count unchanged in Q2 2026.
Pfizer made up 0.09% of Eurizon SLJ Capital's portfolio in Q2 2026, its #116 holding.
Eurizon SLJ Capital first reported a position in Pfizer in Q1 2026 and has held it in 2 quarters since.
Eurizon SLJ Capital's Pfizer position peaked at $278K in Q1 2026.
2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Eurizon SLJ Capital's 13F filing for Q2 2026, filed 3 Aug 2026.